HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)

DRUG2 trials

Sponsors

Global Alliance for TB Drug Development, Thirty Respiratory Limited

Conditions

Pulmonary TuberculosesTuberculosis, Pulmonary, Drug SensitiveTuberculosis, Pulmonary, Multi Drug-resistant

Phase 2

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

RecruitingNCT07073638

Thirty Respiratory LimitedPulmonary Tuberculoses

Start: 2025-10-13End: 2026-11-15Target: 24Updated: 2026-01-12

Phase 3

Shortening Treatment by Advancing Novel Drugs

CompletedNCT02342886

Global Alliance for TB Drug DevelopmentTuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant

Start: 2015-02-28End: 2018-05-31Updated: 2019-03-26

Related Papers

Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial

BMC Infectious Diseases2016-08-2732 citations